Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB:ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party’s asset valuation acceptable to the Endonovo board. It was further agreed, that SofPulse, Inc. will prepare to fulfill the regulatory requirements for a NASDAQ listing following the sale’s completion.
Related news for (ENDV)
- Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
- Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
- Endonovo’s SofPulse® Secures Taiwan FDA Approval
- Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution